Oral MANF microcapsule and application thereof in preparation of preparation for treating ulcerative colitis
Through the combination of sodium alginate/hyaluronic acid composite hydrogel microspheres and enteric polymer materials, export MANF microcapsules were prepared, which solved the problem of maintaining protein drugs in the gastrointestinal environment and achieved the MANF protein Effective delivery to the colon site significantly improves the therapeutic effect of ulcerative colitis and reduces the risk of side effects.
Patent Information
- Application Number
- CN202411304242.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-19
AI Technical Summary
In the prior art, protein drugs such as MANF are difficult to maintain normal function in the gastrointestinal environment, especially when administered orally, and are difficult to effectively deliver to the colon site, resulting in poor treatment effect of ulcerative colitis and high risk of side effects.
Oral MANF microcapsules are prepared by airflow shearing method by using sodium alginate/hyaluronic acid composite hydrogel microspheres to combine enteric polymer materials to prepare oral MANF microcapsules through airflow shearing to achieve protective transmission and targeted release of drugs in the gastrointestinal tract and ensure MANF protein Effective in colon fluid.
Oral MANF microcapsules can effectively reduce the damage of ulcerative colitis and improve intestinal flora. The efficacy is better than intravenous injection. Oral administration is better at the same dose, and the oral dose is halved can still achieve similar effects intravenous injection. , no acute toxic side effects.
Smart Images

Figure CN119033726A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of oral pharmaceutical preparations, and particularly relates to an oral MANF microcapsule and an application thereof in preparing a preparation for treating ulcerative colitis. Background Art
[0002] Ulcerative colitis (UC) is a chronic inflammatory disease of the colon and rectum that is prone to relapse and is the main subtype of inflammatory bowel disease (IBD). IBD has been shown to be associated with multiple factors, such as immune system dysfunction, genetic susceptibility, dysbiosis, pathogenic infection, and environmental factors. In clinical practice, many small molecule drugs (such as corticosteroids, aminosalicylates, and immunomodulators) can be used for IBD patients. However, systemic use of these drugs often carries the risk of severe side effects and cannot prevent relapses.
[0003] In recent decades, the development of many biological therapies has brought new perspectives to the treatment of IBD. In 2005, infliximab (IFX) became the first biologic approved for UC. Since then, many biologics such as adalimumab, golimumab, vedolizumab, and ustekinumab have been approved. Mesencephalicastrocyte-derived neurotrophic factor (MANF) is a secretory protein induced by endoplasmic reticulum stress. It has been reported that MANF has an alleviating effect on diseases related to endoplasmic reticulum stress, such as Parkinson's disease, Alzheimer's disease, stroke, retinal regeneration, and diabetes. Recently, our research group found that myeloid-specific knockout of MANF can upregulate the expression of BATF2 and promote Ly6C hi CX3CR1 int The recruitment of inflammatory macrophages and the accumulation of Th17 cells further aggravate colon inflammation. Intravenous injection of recombinant human MANF protein can significantly alleviate acute ulcerative colitis in mice by activating the innate immune inflammatory response. However, all studies on the therapeutic application of recombinant human MANF protein to date are based on local injection and intravenous injection.
[0004] Oral administration is convenient, safe, and is the preferred route of administration for patients with chronic gastrointestinal diseases. However, the pH values of the gastrointestinal tract (GIT) vary greatly: stomach (1 ~ 2.5), small intestine (5.5 ~ 7), and large intestine (5.5 ~ 7.5). The digestive tract is also rich in a variety of enzymes and microorganisms. In such a harsh gastrointestinal environment, it is extremely challenging to maintain the normal function of drugs, especially protein drugs. Therefore, it is of great significance to develop an oral formulation of MANF. Summary of the invention
[0005] In view of the shortcomings of human recombinant MANF protein in the clinical treatment of ulcerative colitis (UC), the present invention provides an oral MANF microcapsule preparation for the treatment of ulcerative colitis, achieving a major breakthrough from intravenous injection to oral administration. The present invention successfully delivers MANF protein to the colon by oral administration through the development of an oral MANF microcapsule preparation, and confirms at the animal level that it can reduce the damage of ulcerative colitis in mice induced by dextran sulfate sodium (DSS), improve intestinal flora, and the efficacy of oral administration is better than intravenous injection at the same MANF dose. Even if the oral MANF dose is halved, the efficacy similar to that of intravenous injection can be obtained. Specifically, the present invention is implemented using the following technical solutions: Firstly, the present invention provides an oral MANF microcapsule for treating ulcerative colitis, which comprises sodium alginate / hyaluronic acid composite hydrogel microspheres loaded with MANF and an enteric polymer material coated on the surface of the microspheres.
[0006] Secondly, the present invention also provides a method for preparing the above-mentioned oral MANF microcapsules, which can be prepared by the following steps: Sodium alginate (SA), hyaluronic acid (HA) and MANF protein solution were mixed evenly in proportion, and the mixed solution of sodium alginate, hyaluronic acid and MANF protein solution was dropped into calcium chloride solution by controlling the gas flow rate using air flow shear method to fully cross-link to obtain sodium alginate / hyaluronic acid composite hydrogel microspheres loaded with MANF protein. The microspheres were freeze-dried after centrifugation and further coated with enteric polymer materials on the surface.
[0007] For the preparation method described above, it can be selected that the concentration of the sodium alginate solution is 1-2.5%, the concentration of the hyaluronic acid solution is 0.1-1%, preferably 0.1-0.5%, and the concentration of the calcium chloride solution is 2-10%, preferably 2-5%. The concentration of the MANF protein in the sodium alginate / hyaluronic acid mixed solution is not higher than 10 mg / mL, preferably 1-5 mg / mL, and more preferably 1-3 mg / mL. The volume ratio of the sodium alginate / hyaluronic acid mixed solution to the calcium chloride solution is 1-3:1. The concentration of the calcium chloride solution is 2-10%. The gas flow rate of the air flow shear is 0.2-0.8 L / min.
[0008] For the preparation method described above, a method that can be selected as a preferred embodiment may be: the preparation method of the oral MANF microcapsules is to mix 1%-2.5% sodium alginate and 0.1%-1% hyaluronic acid evenly, then add MANF protein thereto so that the final concentration is not higher than 10 mg / mL, and drip the mixed solution into 2-10% calcium chloride by air flow shearing method for full cross-linking; freeze-dry the microspheres after centrifugation, and take 10-50 mg of the freeze-dried microspheres and disperse them in a mixed solution of acetone and ethanol containing 2-10 mL 4-6% of enteric polymer material (acetone / ethanol volume ratio 2:1); transfer the mixture to light liquid paraffin containing 0.5-2% span 80, and stir at 500-1000 rpm to volatilize the solvent; centrifuge and wash with n-hexane and deionized water respectively, and finally obtain sodium alginate / hyaluronic acid composite hydrogel microspheres loaded with MANF protein wrapped by enteric polymer material, i.e., oral MSH@E microcapsules, which are stored at -20°C. The MSH@E microcapsules obtained in this way have high drug loading (5-8%) and encapsulation efficiency (78-85%).
[0009] Furthermore, as a better embodiment, the preparation method of the oral MANF microcapsules is to mix 1.5% sodium alginate and 0.25% hyaluronic acid evenly, then add MANF protein to make the final concentration of 2 mg / mL, then use an air flow shear device to drop the mixed solution into a 2% calcium chloride solution for full crosslinking, centrifuge and freeze-dry the microspheres, take 50 mg of the freeze-dried microspheres and disperse them in 10 mL of a mixed solution of acetone and ethanol containing 5% Eudragit S 100 (acetone / ethanol volume ratio 2:1); transfer the mixture to light liquid paraffin containing 1% span 80, stir at 1000 rpm to evaporate the solvent (for more than 3 hours); centrifuge and wash with n-hexane and deionized water to finally obtain MSH@E microcapsules, which are stored at -20°C. The drug loading (6%) and encapsulation efficiency (80%) of the obtained MSH@E microcapsules can reach a better state.
[0010] The oral MANF microcapsule prepared by the present invention has a simple preparation method and mild preparation conditions, and the biological activity of the MANF protein is protected to the greatest extent. The microcapsule has pH sensitivity, and can achieve very little release of the drug in the upper digestive tract and time-dependent release in the colonic fluid. As natural polymer materials, hyaluronic acid and sodium alginate have good biocompatibility. CD44 is highly expressed on the surface of macrophages in the inflammatory site of colitis, and hyaluronic acid can specifically target CD44 molecules. The MANF protein can be combined with the macrophage through non-covalent bonds such as hydrogen bonds and electrostatic effects to achieve enrichment in the inflammatory area, thereby better achieving targeted therapy.
[0011] Thirdly, the oral MANF microcapsules of the present invention can be used in the preparation of preparations for treating ulcerative colitis. Of course, the oral MANF microcapsules obtained by the above-mentioned preparation method can also be used in the preparation of preparations for treating ulcerative colitis.
[0012] The oral MANF microcapsules prepared by the present invention can be used for long-term oral treatment of ulcerative colitis. Animal experiments have confirmed that MANF can be effectively delivered to the inflammatory tissue of the colon of ulcerative colitis mice. The results of body weight, DAI score and histopathological staining show that the efficacy of the oral MANF microcapsules is significantly better than that of intravenous injection at the same dose. Multiple high-dose oral administration to experimental animals showed no acute toxic side effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 : Schematic diagram of the preparation of oral MANF microcapsules and their application in the treatment of colitis.
[0014] Figure 2 : SEM images of MSH and MSH@E.
[0015] Figure 3 : In vitro gastrointestinal simulated release profiles of MSH@E, MECC and MSH (SGF-2 h in simulated gastric fluid, SIF-3 h in simulated small intestinal fluid and SCF-12 h in simulated colonic fluid).
[0016] Figure 4 : Biocompatibility evaluation of MSH@E. (A) Body weight change, (B) HE staining images of major organ tissues.
[0017] Figure 5 : In vivo fluorescence imaging of normal mice and DSS-induced colitis mice after oral administration of MS@E and MSH@E and the corresponding gastrointestinal tissue fluorescence imaging.
[0018] Figure 6 : His immunohistochemical staining of colon tissue sections of colitis mice after oral administration of MS@E and MSH@E. The lower figure is a partial enlargement of the upper figure. (A) Negative control, (B) PBS group, (C) MS@E and (D) MSH@E.
[0019] Figure 7 :In vitro anti-inflammatory effect of MSH@E. Expression levels of (A) IL-6, (B) IL-1β, (C) TNF-α, and (D) MPO in the cell supernatant of each group after adding SH@E, MANF, and MSH@E to the LPS-induced RAW 264.6 cell inflammation model Figure 8:Evaluation of the efficacy of MSH@E in ulcerative colitis. (A) Schematic diagram of the modeling and treatment process of ulcerative colitis mice. C57BL / 6J mice were given drinking water containing DSS (3.5%, w / v) for 7 days and received drug treatment from day 4 to day 7, (B) body weight change, (C) DAI score, (D) colon weight, (E) colon length.
[0020] Fig. 9 : HE staining images of colon tissue sections of mice in each experimental group after treatment with different drugs. The lower figure is a partial enlarged view of the upper figure. (A) Healthy mice, (B) PBS group, (C) SH@E, (D) MS@E group, (E) MANF (iv) group, (F) ½MSH@E group, (G) MSH@E group and (H) 5-ASA group.
[0021] Fig.10 : Levels of IL-6 (A), IL-1β (B), TNF-α (C) and MPO (D) in the serum of mice in each experimental group after treatment with different drugs.
[0022] Fig.11 :16S (rRNA) sequencing analysis of intestinal microbiota in colitis mice after oral administration of MSH@E. (A) Chao index, (B) Shannon index, (C) relative abundance of Escherichia-Shigella and (D) relative abundance of Akkermansia. DETAILED DESCRIPTION
[0023] The following embodiments are further descriptions of the content of the present invention as an explanation of the technical content of the present invention, but the essential content of the present invention is not limited to the following embodiments. Ordinary technicians in this field can and should know that any simple changes or replacements based on the essential spirit of the present invention should fall within the scope of protection required by the present invention. Example 1
[0024] Preparation of oral MANF microcapsules (MSH@E): (1) Prepare an aqueous solution with a final concentration of 1.5% sodium alginate SA and 0.25% hyaluronic acid HA; (2) Add MANF protein to the above solution to make the final concentration of 2 mg / mL. After mixing, add the mixed solution to the air flow shear device, adjust the air flow to 0.6 L / min, and drip it dropwise into the 2% CaCl2 solution, stirring for 10 min. (3) Collect the microspheres and wash them twice with deionized water; (4) Freeze-dry, seal and store at -20°C for future use; (5) Weigh 0.5 g of Eudragit S 100 and dissolve it in 10 mL of a mixed solvent of ethanol and acetone (acetone / ethanol volume ratio 2:1); (6) Weigh 50 mg of MANF-loaded sodium alginate / hyaluronic acid microspheres and add them to the solution in (5); (7) Take 70 mL of liquid paraffin and add Span 80 to a final concentration of 1%; (8) Add solution (5) to (7) and stir at 1000 rpm / min at room temperature until the solvent is completely evaporated; (9) The microspheres were collected by centrifugation, washed with n-hexane and deionized water, freeze-dried, and sealed and stored at -20 °C until use.
[0025] The morphology of the hydrogel microspheres prepared in Example 1 was observed by scanning electron microscopy. Figure 2 As shown, it shows that the microcapsules prepared by the present invention are spherical. The drug loading of the MSH@E microcapsules obtained by the present invention is 6% and the encapsulation rate is 80%.
[0026] Comparative Example 1: Preparation of oral microcapsules (SH@E) without adding MANF protein The difference from Example 1 is that no MANF protein solution is added in step (2).
[0027] Comparative Example 2: Preparation of oral MANF microcapsules (MS@E) without hyaluronic acid HA Preparation of MANF-loaded Eudragit S 100-coated sodium alginate hydrogel microspheres (MS@E). The difference from Example 1 is that the step (1) of adding hyaluronic acid is omitted.
[0028] Comparative Example 3: Preparation of MANF / sodium alginate / hyaluronic acid composite hydrogel microspheres (MSH) without enteric coating.
[0029] The difference from Example 1 is that the Eudragit S 100 coating is not performed in steps (5-9).
[0030] Comparative Example 4: Preparation of MANF Enteric-coated Capsules (MECC) The MANF protein was directly encapsulated in commercial enteric-coated capsules (YG00-2, Yuyan Instrument Co., Ltd.). Example 2
[0031] In vitro release experiment of oral MANF microcapsules (MSH@E).
[0032] Appropriate amounts of oral MANF microcapsules (MSH@E), MANF enteric-coated capsules (MECC) and MANF sodium alginate / hyaluronic acid composite hydrogel microspheres (MSH) were placed in artificial gastrointestinal fluid at different pH values and incubated. The release of proteins at different time points was determined using the Coomassie brilliant blue method to investigate the degradation behavior of the modified microspheres at different pH values in vivo. Figure 3 As shown in the figure, the protein release of microspheres in artificial gastric juice within 2 hours is almost 0. When transferred to artificial small intestinal juice, the cumulative protein release is less than 5%, while the protein is completely released in artificial colonic juice within 12 hours. The release of the comparative MANF enteric-coated capsules in artificial gastric juice and small intestinal juice is higher than that of oral MANF microcapsules, and they are rapidly and massively released after entering the colonic juice. The comparative MANF sodium alginate hyaluronic acid composite hydrogel microspheres (MSH) are slightly released in the small intestinal juice without Eudragit S 100 coating, and are completely released in the colonic juice within 8 hours, indicating that oral MANF microcapsules can effectively protect MANF in the upper digestive tract, and can have a good delayed release effect after entering the colon. Example 3
[0033] Biocompatibility evaluation of oral MANF microcapsules (MSH@E): In vivo biocompatibility experiment, 12 female C57BL / 6 mice were divided into 2 groups and orally administered with PBS and MSH@E, respectively. The MSH@E group was given MANF at a dose of 750 mg / kg for six consecutive days, and the mice were killed after fasting for 24 hours. The body weight of the mice was recorded daily during the administration period, and the main organs and gastrointestinal tissues (heart, liver, spleen, lung, kidney, colon) were collected for hematoxylin-eosin staining analysis. The results are shown in Figure 4 As shown, there was no significant difference in the body weight of the mice in the experimental group compared with the control group ( Figure 4 A), Hematoxylin-eosin staining results showed that the MSH@E hydrogel microsphere group did not cause pathological changes and inflammatory lesions in the organs of mice compared with the control group ( Figure 4 B). Example 4
[0034] Targeting evaluation of oral MANF microcapsules (MSH@E).
[0035] The anthocyanin fluorescent dye Cy 5 was coupled to the MANF protein in the composite hydrogel microspheres, and then the same doses of PBS, Cy5, MS@E and MSH@E (Cy 5: 0.5 mg / kg) were orally administered to healthy mice and colitis mice, respectively. At 2, 6, 12 and 24 hours, the fluorescence of the mouse abdomen was recorded using an optical imaging system. The mice were killed 24 hours after administration, and the colon was collected for fluorescence imaging. The results are shown in Figure 5As shown, the fluorescence intensity of the Cy5, MS@E and MSH@E groups gradually weakened over time, and the Cy5 group had almost no fluorescence after 24 hours, while the fluorescence intensity of the hyaluronic acid HA-modified MSH@E group was still high. Gastrointestinal tissue imaging showed that the hyaluronic acid-modified MSH@E group was significantly enriched in the colon. In addition, the fluorescence of MSH@E-treated colitis mice was stronger than that of healthy mice. These results indicate that MSH@E retains a longer time in the colon tissue of DSS-induced colitis mice, confirming that the addition of HA increases the in vivo targeting properties of MSH@E. The MANF protein used in this experiment carries a histidine His tag, and immunohistochemical labeling of His shows a brown-yellow color ( Figure 6 ), compared with the MS@E group, the MSH@E group showed a more obvious brown-yellow color, indicating that a large amount of MANF protein was successfully delivered to the colon, which suggests that HA plays an important role in MSH@E targeting the colon inflammation site. Example 5
[0036] In vitro anti-inflammatory evaluation of oral MANF microcapsules (MSH@E).
[0037] In all cell experiments, RAW 264.7 cells were cultured with MSH@E extract. Usually, after MSH@E was incubated in RPMI1640 medium for 72 h, the supernatant was collected and centrifuged to obtain MSH@E extract. After the cells were inoculated in a 6-well plate overnight, they were co-cultured with LPS (1 µg / mL) and then co-incubated with MSH@E extract (322 µg / mL, equivalent to 20 μg / mL of MANF protein) for 24 h. Subsequently, the activity levels of myeloperoxidase (MPO) (Boster, EK0943), IL-6 (Boster, EK0411), IL-1β (Boster, EK0394) and TNF-α (Boster, EK0527) in the cell supernatant were detected by ELISA. The results of ELISA showed that after LPS activation, the levels of IL-6, IL-1β, TNF-α and MPO increased. After treatment with MANF and MSH@E, the levels of IL-6, IL-1β, TNF-α, and MPO decreased. It is worth noting that when the concentration of MANF in MSH@E was the same as that in the MANF group (20 μg / mL), the anti-inflammatory effect of MSH@E was better than that of the MANF group ( Figure 7 AD). Example 6
[0038] Evaluation of the efficacy of oral MANF microcapsules (MSH@E).
[0039] Mice with ulcerative colitis were randomly divided into seven groups: PBS-colitis mice were orally administered with PBS, 5-ASA-colitis mice were orally administered with 5-ASA (1 mg / kg), SH@E-colitis mice were orally administered with SH@E (16 mg / kg), MS@E-colitis mice were orally administered with MS@E (equivalent to MANF 1 mg / kg), MANF (iv)-colitis mice were intravenously administered with MANF (1 mg / kg), MSH@E-colitis mice were orally administered with MS@E (equivalent to MANF 1 mg / kg), and 1 / 2 MSH@E-colitis mice were orally administered with half the dose of MSH@E (equivalent to MANF 0.5 mg / kg). Healthy mice served as the control group. Figure 8 As shown in A, mice in each experimental group were given the drug once a day from day 4 to 7. During the treatment period, body weight, rectal bleeding and stool were checked every day, and the disease activity index (DAI) was determined. On day 10, the mice were killed, spleen and colon were collected, spleen weight and colon length were recorded; colon tissue was sliced histologically; blood was collected from the mouse orbit to detect the content of inflammatory factors in serum; and the feces of the mice were collected to evaluate the composition and abundance of the mouse intestinal flora using 16S rRNA gene sequencing.
[0040] Weight results are as follows Figure 8 As shown in B, the body weight of mice in the DSS modeling group gradually decreased compared with the healthy control group, and decreased by about 40% on the 10th day. Compared with the PBS group, the body weight of mice in the oral gavage MS@E, 1 / 2 MSH@E, MSH@E groups and the tail vein injection MANF group was on a downward trend, while the body weight loss of mice in the oral MS@E, 1 / 2 MSH@E, MSH@E groups and the tail vein injection MANF groups gradually slowed down, and the body weight reduction of mice in the MSH@E group was the most obvious. Consistent with the results of body weight changes, the disease activity index ( Figure 8 C), colon weight ( Figure 8 D) and colon length ( Figure 8 E) The results also showed that MSH@E had the best therapeutic effect. HE staining results ( Fig. 9 ) showed that the colon of mice in the DSS group showed obvious immune cell infiltration, mucosal tissue loss, and disappearance of goblet cells and crypt structures, while the crypt structure in the MSH@E group was partially restored and tissue damage was alleviated. Elisa results showed that MSH@E treatment could significantly reduce the levels of IL-6, IL-1β, TNF-α and MPO in mice with colitis, indicating that MSH@E can alleviate colitis by regulating the levels of MPO, IL-6, IL-1β and TNF-α ( Fig.10 At the same time, the bacterial community composition of colitis mice was significantly changed compared with that of healthy mice. Oral administration of MSH@E significantly increased Chao 1 and Shannon diversity indices, species richness, and microbial community diversity ( Fig.11 A, B). It has been reported that the abundance of Escherichia -Shigella, a highly virulent strain of Proteobacteria, was significantly increased in mice with inflammatory bowel disease. Akkermansia belongs to the phylum Verrucomicrobia and plays a vital role in maintaining the integrity of the intestinal barrier and is considered a beneficial probiotic. MSH@E microcapsules reduced the relative abundance of Shigella and increased the relative abundance of Akkermansia ( Fig.11 C, D). The above results show that the abundance and diversity of intestinal flora in colitis mice after MSH@E treatment tend to return to the level of healthy mice, indicating that ulcerative colitis is effectively improved. The oral MANF microcapsules of the present invention can be used for long-term oral treatment of ulcerative colitis.
[0041] It should be noted that the above-mentioned technical contents of the present invention are only for explanation and clarification to enable those skilled in the art to understand the technical essence of the present invention, so the technical contents are not used to limit the substantial protection scope of the present invention. The substantial protection scope of the present invention shall be subject to the claims. Those skilled in the art should know that any modification, equivalent substitution and improvement based on the substantial spirit of the present invention shall be within the substantial protection scope of the present invention.
Claims
1. An oral MANF microcapsule, comprising sodium alginate / hyaluronic acid composite hydrogel microspheres loaded with MANF, wherein the surface of the composite hydrogel microspheres is coated with an enteric polymer material.
2. The method for preparing the oral MANF microcapsules according to claim 1, characterized in that: The sodium alginate solution, hyaluronic acid solution and MANF protein solution are mixed evenly in proportion, and the mixed solution of the sodium alginate solution, hyaluronic acid solution and MANF protein solution is dropped into a calcium chloride solution by controlling the gas flow rate using the air flow shear method to fully cross-link to obtain sodium alginate / hyaluronic acid composite hydrogel microspheres loaded with MANF protein. The microspheres are freeze-dried after centrifugation and further coated with enteric polymer materials on the surface.
3. The preparation method according to claim 2, characterized in that: The concentration of the sodium alginate solution is 1-2.5%, the concentration of the hyaluronic acid solution is 0.1-1%, preferably 0.1-0.5%, and the concentration of the calcium chloride solution is 2-10%, preferably 2-5%.
4. The preparation method according to claim 2, characterized in that: The concentration of the MANF protein in the sodium alginate / hyaluronic acid mixed solution is no higher than 10 mg / mL, preferably 1-5 mg / mL, more preferably 1-3 mg / mL.
5. The preparation method according to claim 2, characterized in that: The volume ratio of the MANF / sodium alginate / hyaluronic acid mixed solution to the calcium chloride solution is 1-3:
1.
6. The preparation method according to claim 2, characterized in that: The gas flow rate is 0.2-0.8 L / min.
7. The preparation method according to claim 2, characterized in that: The enteric polymer material is Eudragit S 100.
8. The preparation method according to any one of claims 2 to 7, characterized in that: The preparation method of the composite hydrogel microspheres is as follows: 1-2.5% sodium alginate solution and 0.1-1% hyaluronic acid solution are mixed evenly, and then MANF protein is added thereto so that the concentration of MANF protein is not higher than 10 mg / mL, and then the mixed solution is dripped into 2-10% calcium chloride solution under the control of gas flow rate for full cross-linking, and the microspheres are freeze-dried after centrifugation; 10-50 mg of the freeze-dried microspheres are dispersed in 2-10 mL of a mixed solution of acetone and ethanol containing 4-6% enteric polymer materials, and the volume ratio of acetone / ethanol is 2:1; the mixture is transferred to light liquid paraffin containing 0.5-2% Span 80, and then the solvent is evaporated by stirring at 500-1000 rpm; centrifugation and washing with n-hexane and deionized water respectively, finally obtaining sodium alginate / hyaluronic acid composite hydrogel microspheres loaded with MANF wrapped by enteric polymer materials, namely oral MANF microcapsules MSH@E.
9. Use of the oral MANF microcapsules according to claim 1 in the preparation of a preparation for treating ulcerative colitis.
10. Use of the oral MANF microcapsules obtained by the preparation method according to any one of claims 2 to 6 in the preparation of a preparation for treating ulcerative colitis.
Citation Information
Patent Citations
Application of midbrain astrocyte-derived neurotrophic factor in treatment of ulcerative colitis
CN112587654A
Use of microparticles containing genetically modified cells in the treatment of neurodegenerative diseases
US20110212060A1
Targeted conjugates and particles and formulations thereof
US20170151339A1
Cited By
Oral composite microsphere for treating ulcerative colitis based on intestinal ROS storm pathological axis regulation as well as preparation method and application of oral composite microsphere
CN121818550A
